Top

Published in:

01-10-2012 | Review

Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies

Authors: Nathalie Druesne-Pecollo, Mathilde Touvier, Emilie Barrandon, Doris S. M. Chan, Teresa Norat, Laurent Zelek, Serge Hercberg, Paule Latino-Martel

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Abstract

Several observational studies have investigated the role of body mass index (BMI) in second primary cancer incidence in women with breast cancer. We conducted a systematic review and meta-analysis of the evidence to assess the strength of this association. PubMed and Embase were searched for observational studies up to May 2012, and the reference lists of studies included in the analysis were examined. Random effects models were used to estimate summary relative risks (RRs) and 95 % confidence intervals (CIs). Thirteen prospective studies, five cohort and eight nested case–control studies, were included. In categorical meta-analyses of BMI, obesity was associated to significantly increased risks of contralateral breast (RR = 1.37, 95 % CI: 1.20–1.57), breast (RR = 1.40, 95 % CI: 1.24–1.58), endometrial (RR = 1.96, 95 % CI: 1.43–2.70), and colorectal (RR = 1.89, 95 % CI: 1.28–2.79) second primary cancers. For a BMI increase of 5 kg/m², dose–response meta-analyses resulted in significantly increased RRs of 1.12 (95 % CI: 1.06–1.20) and 1.14 (95 % CI: 1.07–1.21) for contralateral breast and breast second primary cancers, respectively. The summary RR for endometrial second primary cancers was 1.46 (95 % CI: 1.17–1.83) for a 5-unit increment. This result emphasizes the importance of prevention policies aiming to reduce overweight and obesity prevalence. Clinical trials in breast cancer patients with excess body weight evaluating the effect of normal weight restoration on second primary cancer incidence are needed.

Available only for authorised users

Ferlay J, Shin HR, Bray F et al. (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr. Accessed May 31, 2011

Curtis RE, Freedman DM, Ron E et al. (2006) New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302, Bethesda, MD

Mellemkjaer L, Friis S, Olsen JH et al (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292PubMedCrossRef

Brown LM, Chen BE, Pfeiffer RM et al (2007) Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 106:439–451PubMedCrossRef

World Cancer Research Fund and American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DC

Reeves GK, Pirie K, Beral V et al (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335:1134PubMedCrossRef

Majed B, Moreau T, Senouci K et al (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111:329–342PubMedCrossRef

Majed B, Dozol A, Ribassin-Majed L et al (2011) Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Res Treat 126:729–738PubMedCrossRef

Majed B, Ribassin-Majed L, Asselain B (2011) Overweight breast cancer survivors are at increased risk of contralateral breast cancers at the long term follow-up. Am J Epidemiol 173(suppl 11): S235

10.

Li CI, Daling JR, Tang MTC, Malone KE (2011) Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 125:545–551PubMedCrossRef

11.

Bernstein JL, Thompson WD, Risch N, Holford TR (1992) Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925–936PubMed

12.

Horn PL, Thompson WD (1988) Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol 128:309–323PubMed

13.

Dignam JJ, Wieand K, Johnson KA et al (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467–1476PubMedCrossRef

14.

Li CI, Malone KE, Porter PL, Daling JR (2003) Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89:513–518PubMedCrossRef

15.

Dignam JJ, Wieand K, Johnson KA et al (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97:245–254PubMedCrossRef

16.

Majed B, Moreau T, Senouci K et al (2009) Stoutness and prognosis of female non-metastatic breast cancer: results from a French observational cohort study. Bull Cancer 96:531–541PubMed

17.

Storm HH, Andersson M, Boice JD Jr et al (1992) Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 84:1245–1250PubMedCrossRef

18.

Cook LS, White E, Schwartz SM et al (1996) A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 7:382–390PubMedCrossRef

19.

Li CI, Daling JR, Porter PL et al (2009) Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 27:5312–5318PubMedCrossRef

20.

Brooks JD, John EM, Mellemkjaer L et al (2012) Body mass index and risk of second primary breast cancer: the WECARE Study. Breast Cancer Res Treat 131:571–580PubMedCrossRef

21.

Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM (2007) Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 105:195–207PubMedCrossRef

22.

Ewertz M, Machado SG, Boice JD Jr, Jensen OM (1984) Endometrial cancer following treatment for breast cancer: a case–control study in Denmark. Br J Cancer 50:687–692PubMedCrossRef

23.

Pukkala E, Kyyrönen P, Sankila R, Holli K (2002) Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case–control study. Int J Cancer 100:337–341PubMedCrossRef

24.

Kmet LM, Cook LS, Weiss NS et al (2003) Risk factors for colorectal cancer following breast cancer. Breast Cancer Res Treat 79:143–147PubMedCrossRef

25.

Sánchez L, Lana A, Hidalgo A et al (2008) Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev 17:406–413PubMedCrossRef

26.

Greenland S, Longnecker M (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301–1309PubMed

27.

Bekkering GE, Harris RJ, Thomas S et al (2008) How much of the data published in observational studies of the association between diet and prostate or bladder cancer is usable for meta-analysis? Am J Epidemiol 167:1017–1026PubMedCrossRef

28.

Krueger H, McLean D, Williams D (2008) The prevention of second primary cancers. Prog Exp Tumor Res Basel Karger 40: I–VIII

29.

Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef

30.

Begg CB, Davey SG, Schneider M, Minder C (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef

31.

Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578PubMedCrossRef

32.

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591PubMedCrossRef

33.

Roberts DL, Dive C, Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61:301–316PubMedCrossRef

34.

Goodwin PJ, Esplen MJ, Winocur J (1995) Development of a weight management program in women with newly diagnosed locoregional breast cancer. In: Bitzer J, Stauber M (eds) Psychosomatic obstetrics and gynecology. Monduzzi Editore, International Proceedings Division, Bologna, pp 491–496

35.

Ryu SY, Kim CB, Nam CM et al (2001) Is body mass index the prognostic factor in breast cancer? A meta-analysis. J Korean Med Sci 16:610–614PubMed

36.

Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635PubMedCrossRef

37.

Chlebowski RT, Weiner JM, Reynolds R et al (1986) Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat 7:23–30PubMedCrossRef

38.

Camoriano JK, Loprinzi CL, Ingle JN et al (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8:1327–1334PubMed

39.

Bonomi P, Bunting N, Fishman D et al (1984) Weight gain during adjuvant chemotherapy or hormone-chemotherapy for stage II breast cancer evaluated in relation to disease free survival (DFS). Breast Cancer Res Treat 4:339

40.

McTiernan A, Irwin M, VonGruenigen V (2010) Weight, physical activity, diet, and prognosis in breast and gynaecologic cancers. J Clin Oncol 28:4074–4080PubMedCrossRef

41.

Holmes MD, Chen WY, Feskanich D et al (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486PubMedCrossRef

42.

Abrahamson PE, Gammon MD, Lund MJ et al (2006) Recreational physical activity and survival among young women with breast cancer. Cancer 107:1777–1785PubMedCrossRef

43.

Pierce JP, Stefanick ML, Flatt SW et al (2007) Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25:2345–2351PubMedCrossRef

44.

Holick CN, Newcomb PA, Trentham-Dietz A et al (2008) Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 17:379–386PubMedCrossRef

45.

Irwin M, Smith AW, McTiernan A et al (2008) Association of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol 26:3958–3964PubMedCrossRef

46.

Sternfeld B, Weltzien E, Quesenberry CP Jr et al (2009) Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. Cancer Epidemiol Biomarkers Prev 18:87–95PubMedCrossRef

47.

Ibrahim EM, Al-Homaidh A (2011) Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 28:753–765PubMedCrossRef

48.

Rock CL, Doyle C, Demark-Wahnefried W et al (2012) Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. doi:10.3322/caac.21142. [Epub ahead of print]

49.

Chlebowski RT, Blackburn GL, Thomson CA et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98:1767–1776PubMedCrossRef

50.

Pierce JP, Natarajan L, Caan BJ et al (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA 298:289–298PubMedCrossRef

Title: Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies
Authors: Nathalie Druesne-Pecollo
Mathilde Touvier
Emilie Barrandon
Doris S. M. Chan
Teresa Norat
Laurent Zelek
Serge Hercberg
Paule Latino-Martel
Publication date: 01-10-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2187-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Preoperative breast MRI in early-stage breast cancer

Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer

Recommendations for the aesthetic evaluation of breast cancer conservative treatment

Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer

Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence

Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer